Chicago-Women with stress urinary incontinence receiving an investigationalagent designed to inhibit two key neurotransmitters significantly showeda reduced number of weekly incontinence episodes and improvements in qualityof life compared with patients receiving placebo. The drug, duloxetine,is dual reuptake inhibitor of serotonin and norepinephrine currently inphase III development.
